Moxifloxacin safety data review
|
|
- Lynette Joseph
- 6 years ago
- Views:
Transcription
1 Moxifloxacin safety data review Paul M. Tulkens, MD, PhD * a Cellular and Molecular Pharmacology Unit & Centre for Clinical Pharmacy Louvain Drug Research Institute Université catholique de Louvain, Brussels, Belgiuma * also Emeritus Professor of Human Biochemistry and Biochemical Pathology Université de Mons/Hainaut, Mons, Belgium Former member of the EUCAST (European Committee for Antibiotic Susceptibility Testing) steering committee founding member and past-president of the International Society of Anti-infective Pharmacology 8. Forschungswerkstatt Moxifloxacin 2 Leverkusen -- 7./8. November Leverkusen
2 Einige Wörter Ich bedauere, diese Darstellung nicht auf deutsch geben zu können... Die Deutsche Sprache ist jedoch sowohl sehr schön als auch sehr logisch... Und ich bin ein begeisteter Zuhörer von J.S. Bach's Passionnen oder Operns von Wagner... Aber ich musste bereits alle Tage Französisch, Flämisch und Englisch sprechen... und Deutsch ist für einen Französigsprachigen schwierig... Ich werde versuchen, die Fragen auf deutsch zu verstehen... Die Lokalisierung der Université catholique de Louvain in Brüssel Die Gebäude der medizinischen Fakultät und das Krankenhaus Die Gruppe der Pharmakologie/Toxikologie der Antibiotika 8--2 Leverkusen 2
3 Fluoroquinolone selection: appropriate benefit-risk profiles Paul M. Tulkens, MD, PhD * a Cellular and Molecular Pharmacology Unit & Centre for Clinical Pharmacy Louvain Drug Research Institute Université catholique de Louvain, Brussels, Belgiuma * also Professor of Human Biochemistry and Biochemical Pathology Université de Mons/Hainaut, Mons, Belgium member of the EUCAST (European Committee for Antibiotic Susceptibility Testing) steering committee founding member and past-president of the International Society of Anti-infective Pharmacology 7. Forschungswerkstatt Moxifloxacin 29 Leverkusen June Leverkusen 3
4 Contents of the Presentation All antimicrobials have associated toxicity risks Major non-serious and serious side-effects associated with the main antimicrobials used in the treatment of CAP ( -lactams, macrolides, tetracyclines, fluoroquinolones). Adverse effects of moxifloxacin vs other agents a comprehensive analysis The risk of bacterial failure are guidelines "safe"? Conclusions 8--2 Leverkusen 4
5 All antimicrobials have associated risks * Class Drugs Frequent or serious side effects fluoroquinolones levofloxacin Anaphylactic reactions and allergic skin reactions Clostridium difficile-associated colitis Hematologic toxicity Hepatotoxicity Central nervous system effects: headache, insomnia, dizziness, convulsions Musculoskeletal: tendinopathies Peripheral neuropathy Prolongation of the QTc interval and isolated cases of torsade de pointes Digestive tract: nausea, diarrhoea moxifloxacin * based on an analysis of the respective labelling (SmPC or equivalent) Conclusions (# ): Anaphylactic reactions and allergic skin reactions Clostridium difficile-associated colitis Musculoskeletal: Tendinopathies Peripheral neuropathy Prolongation of the QT interval Central nervous system effects: headache, insomnia, dizziness, convulsions Digestive tract: nausea, diarrhoea All antimicrobials used in RTI are associated with known toxicities The main point will be the recognition of patients at risk (exclusions) The next point will be a correct evaluation of the benefit / risk ratio in the specific environment and for the specific patient Carbonnelle et al., in preparation 8--2 Leverkusen 5
6 The "end result" 8--2 Leverkusen 6
7 Where are we now with moxifloxacin? Hepatotoxicity: is this a real issue? What do the "whole clinical trial data base" tells us? Is moxifloxacin still effective? 8--2 Leverkusen 7
8 Hepatic toxicity of antibiotics Usually idiosyncratic (can be associated with other allergic reactions). Clavulanic acid: genetic deficiency in glutathione S-transferases? 2 (longer latency period than other antibiotics ) Macrolides: related to reactive metabolites (nitrosoalkanes) that covalently bind to proteins, forming modified antigens (immunoallergic hepatitis) 3 Tetracyclines: related to inhibition of mitochondrial -oxidation of fatty acids 4 Fluoroquinolones: remains anecdotal and unpredictable, except for for molecules with substituent-generating reactive intermediates difluoroaniline (temafloxacin and trovafloxacin) 5 cyclopropylamine (trovafloxacin; for which co-exposure to lipopolysaccharide may also be critical) 6. Robles M, Andrade RJ. Rev Esp Quimioter. 28 Dec;2(4): Lucena et al., Hepatology. 28 Aug;48(2): Pessayre et al. J Antimicrob Chemother 985 Jul; 6 Suppl A: Freneaux et al. Hepatology 988 Sep; 8(5): Blum et al. Clin Infect Dis 994 Jun; 8(6): 946-5; Chen et al. N Engl J Med 2 Feb 3; 342(5): 359-6; Lucena et al. Clin Infect Dis 2 Feb; 3(2): 4-6. Sun et al. Chem Res Toxicol 28 Mar; 2(3): Shaw et al. Toxicol Sci. 29 Jan;7(): Leverkusen 8
9 Patients with possible drug-related hepatic disorders in comparative clinical trials (oral moxifloxacin) Moxifloxacin (N=9394) Comparators (N=9359) AE [ADR] (Sub-)SMQ Total Serious Fatal Total Serious Fatal Comprehensive search All cases Liver-related investigations, signs and symptoms * Cholestasis and jaundice of hepatic origin Possible liver-related coagulation and bleeding disturbances Possible drug-related hepatic disorders - severe events only 29 (2.3%) [53 (.6%)] 6 (<.) [3 (<.)] 8--2 Leverkusen 9 [( )] 223 (2.4%) [39 (.5%)] 8 (<.%) [3 (<.%)] 2 (<.%) [ ( )] 8 [2] 4 [2] [] 98 [24] 4 [] [] 3 [9] [] [] 6 [4] [] [] 7 [5] [] [] 3 [8] [] [] 9 [6] 2 [] [] 7 [7] 3 [] [] Hepatitis, non-infectious 7 [7] [] [] 6 [3] [] [] Hepatic failure, fibrosis and cirrhosis and other liver damagerelated 2 [9] [] [] 9 [4] [] [] conditions Liver neoplasms, benign [] [] [] [] [] [] Liver neoplasms, malignant and unspecified [] [] [] 2 [] 2 [] [] AE: adverse event; ADR: adverse drug reaction; SMQ: Standard MedDRA Query The allocation of a liver-related adverse event to any of the sub-smqs is not mutually exclusive. One patient can have one event allocated to several sub-smqs, or several events located to different sub-smqs. In consequence, the overall number of patients identified with the comprehensive search is smaller than the sum of all patients allocated to the sub-sqms. * similar to published studies
10 SMQ-search for "severe events": Hepatic overview by event type/diagnosis Moxifloxacin AE [ADR] Comparator AE [ADR] Total 9 [6] 7 [7] Hepatitis CTC grade 3 (severe) CTC grade <3 (non-severe) Hepatic failure CTC grade 3 (severe) CTC grade <3 (non-severe) Liver disorder CTC grade 3 (severe) CTC grade <3 (non-severe) 3 [2] 4 [4] [] 2 [2] 9 [8] 8--2 Leverkusen [] 5 [3] [] 3 [] 5 [2] Liver neoplasm 2 [] Outcomes Resolved/improved Unchanged Worsened/death Unknown 7 AE: adverse event; ADR: adverse drug reaction Common Terminology Criteria for Adverse Events v3.: AP, GGT, AST, ALT: Grade (mild), >ULN 2.5x ULN; Grade 2 (moderate), >2.5 5.x ULN; Grade 3 (severe), >5. 2.x ULN; Grade 4 (life-threatening), >2.x ULN Total bilirubin: Grade (mild), >ULN.5x ULN; Grade 2 (moderate), >.5 3.x ULN; Grade 3 (severe), >3..x ULN; Grade 5 (lifethreatening), >.x ULN 2 4
11 Crude incidence rates of acute liver injury caused by antibiotics * Incidence rate (CI) Antibiotic population per, users per, prescriptions endpoint reference fluoroquinolones (w/o moxifloxacin) Outpatient clinic, Sweden (995-25).7 (.5-.) International consensus [] moxifloxacin Outpatient clinic, Sweden (995-25).8 (.-.5) International consensus [] cotrimoxazole Saskatchewan Health Plan, Canada ( ). (.2-5.7) 4.9 ( ) International consensus, hospitalisati on [2] erythromycin Saskatchewan Health Plan, Canada ( ) 2. (.7-5.9) 4. ( ) International consensus, hospitalisati on [2] amoxicillinclavulanic acid General practice research database, United Kingdom (99-992) 22.5 ( ) 7.4 ( ) International consensus [3] * see Van Bambeke & Tulkens, Drug Safety (in press) for full Table and details. De Valle et al. Aliment Pharmacol Ther 26 Oct 5; 24(8): Perez et al. Epidemiology 993 Nov; 4(6): Garcia-Rodriguez et al. Arch Intern Med 996 Jun 24; 56(2): Leverkusen
12 An extensive review 8--2 Leverkusen 2
13 An extensive review 8--2 Leverkusen 3
14 An extensive review 8--2 Leverkusen 4
15 Moxifloxacin hepatotoxicity (confirmation) There is no evidence from currently available data that reactions are more frequent than with comparators Clinical trials: Apparent imbalance in drug-related severe events detected in the EU Periodic Safety Report was based on clinically non-severe, non-serious events (the number of serious, or clinically severe ADRs is too small for meaningful conclusions) Spontaneous and registry data: all data show a lower incidence for fluoroquinolones vs macrolides and amoxicillin/clavulanic acid No signal in EBGM analysis conducted by FDA in Leverkusen 5
16 The whole clinical trial data base 8--2 Leverkusen 6
17 The whole clinical trial data base Submitted on 4 November Leverkusen 7
18 Which patients and which comparators? open-label and double-blind actively controlled clinical trials included in the clinical trial database of moxifloxacin 4 mg oncedaily performed by the registration holder (currently Bayer HealthCare) as part of the phase II-IV programmes initiated, completed and with raw data reported to the sponsor between 996 and Leverkusen 8
19 Which global results? 8--2 Leverkusen 9
20 Which global results? AE, ADR and SADR were mainly gastrointestinal disorders and "changes observed during investigations" such as asymptomatic QT prolongation). Incidence rates of hepatic disorders, tendon disorders, surrogates of QT prolongation, serious cutaneous reactions and Clostridium difficile-associated diarrhoea were similar with moxifloxacin and comparators Leverkusen 2
21 And for patients at risk? PO sequential IV age (> 65 y) n = 255 vs. 243 n = 373 vs. 334 n = 7 vs. 9 AE 5 / / 9 83 / 8 ADR 44 / / / 3 SAE 27 / / / 24 SADR 6 / 8 49 / 3 4 / 6 discont. AE 6 / 9 3 / 4 / discont. ADR 78 / / 42 4 / 6 death AE 29 / 32 / 98 3 / death ADR. 3 / 2 / 3 / relative risk estimate (moxifloxacin / comparator) diabetes n = 777 vs. 77 n = 926 vs. 97 n = 8 vs. 72 AE / ADR / SAE / SADR / 2-2 discont. AE / discont. ADR / 2-4 death AE / death ADR. - 2 / relative risk estimate (moxifloxacin / comparator) 8--2 Leverkusen 2
22 And for patients at risk? PO sequential IV renal impairment n = 283 vs. 229 n = 889 vs. 863 n = 23 vs. 28 AE ADR SAE SADR discont. AE discont. ADR death AE death ADR relative risk estimate (moxifloxacin / comparator) hepatic impairment n = 46 vs. 63 n = 83 vs. 96 n = 46 vs. 46 AE ADR SAE SADR discont. AE discont. ADR death AE death ADR relative risk estimate (moxifloxacin / comparator) 8--2 Leverkusen 22
23 And for patients at risk? PO sequential IV cardiac disorders n = 476 vs. 44 n = 476 vs. 36 n = 6 vs. 4 AE ADR SAE SADR discont. AE discont. ADR death AE death ADR relative risk estimate (moxifloxacin / comparator) BMI < 8 n = 38 vs. 365 n = 6 vs. 5 n = 45 vs. 53 AE ADR SAE SADR discont. AE discont. ADR death AE death ADR relative risk estimate (moxifloxacin / comparator) 8--2 Leverkusen 23
24 And what if we compare drugs? A. oral therapy. moxifloxacin vs -lactams risk factor: age > 65 y (n= 99 vs 788) diabetes (n = 282 vs 27) renal impairment (n = 347vs 38) hepatic impairment (n = 47 vs 53) cardiac disorders (n = 526 vs 444) BMI < 8 (n = 7 vs 76) AE ADR 7-5 SAE SADR discont. AE discont. ADR 3 - death AE death ADR 2. moxifloxacin vs macrolides relative risk estimate (moxifloxacin / comparator) risk factor: age > 65 y (n = 252 vs 942) diabetes (n = 329 vs 255) renal impairment (n = 484 vs 427) hepatic impairment (n = 44 vs 64) cardiac disorders (n = 794 vs 623) BMI < 8 (n = vs 4) AE ADR SAE SADR discont. AE discont. ADR death AE death ADR relative risk estimate (moxifloxacin / comparator) 8--2 Leverkusen 24
25 And what if we compare drugs? B. sequential therapy. moxifloxacin vs -lactam alone risk factor: age > 65 y (n= 44 vs 422) diabetes (n = 562 vs 56) renal impairment (n = 329 vs 324) hepatic impairment (n = 89 vs 73) cardiac disorders (n = 438 vs 46) BMI < 8 (n = 4 vs 36) AE ADR SAE SADR 3-3 discont. AE discont. ADR 24-6 death AE death ADR 2. moxifloxacin vs -lactam alone or combined with a macrolide relative risk estimate (moxifloxacin / comparator) risk factor: age > 65 y (n = 223 vs 235) diabetes (n = 69 vs 99) renal impairment (n = 68 vs 6) hepatic impairment (n = 37 vs 42) cardiac disorders (n = 75 vs 68) BMI < 8 (n = 25 vs 25) AE ADR SAE SADR 3 - discont. AE discont. ADR death AE death ADR - - relative risk estimate (moxifloxacin / comparator) 8--2 Leverkusen 25
26 And what if we compare drugs? C. intravenous therapy. moxifloxacin vs -lactam risk factor: age > 65 y (n= 92 vs 9) diabetes (n = 46 vs 33) renal impairment (n = 9 vs 85) hepatic impairment (n = 3 vs 35) cardiac disorders (n = 7 vs 6) BMI < 8 (n = vs 6) AE ADR 2 - SAE SADR discont. AE discont. ADR death AE death ADR 2. moxifloxacin vs another fluroquinolone relative risk estimate (moxifloxacin / comparator) risk factor: age > 65 y (n = 6 vs 74) diabetes (n = 27 vs 3) renal impairment (n = 77 vs 86) hepatic impairment (n = 7 vs 5) cardiac disorders (n = 32 vs 38) BMI < 8 (n = 26 vs 37) AE - ADR - SAE SADR discont. AE - - discont. ADR - - death AE death ADR relative risk estimate (moxifloxacin / comparator) 8--2 Leverkusen 26
27 Conclusions (at this point) The overall safety profile of moxifloxacin is similar to that of comparators from clinical trials More specifically, and with regard to recent questions: Hepatic events reactions were very low and not superior in a statistically significant manner to comparators even if considering patients with hepatic disorders While QTc prolongation were observed, no increase clinical adverse effects were seen even in patients with prexisting cardiac disorders vs. the comparator(s) Specific toxicities (tendonitis, e.g.) remained exceedingly rare with no difference between moxifloxacin and the fluroquinolone comparator Skin events were extremely are and less frequent than with -lactams 8--2 Leverkusen 27
28 But what is "risk"? side effects? therapeutic failure? 8--2 Leverkusen 28
29 Is moxifloxacin still effective? wild type population (EUCAST) clinical breakpoint: EUCAST CLSI amoxicillin cefuroxime (oral) clarithromycin telithromycin cumulative percentage levofloxacin moxifloxacin MIC (mg/l) 8--2 Leverkusen 29
30 Is moxifloxacin still effective? wild type population (EUCAST) clinical breakpoint: EUCAST CLSI 9 8 amoxicillin cefuroxime (oral) S. pneumoniae N= 249 (non-duplicates) clinically-confirmed CAP moxifloxacin clarithromycin 8 7 telithromycin levofloxacin cumulative percentage 3 2 moxifloxacin MIC (mg/l) 8--2 Leverkusen 3
31 Moxifloxacin MIC's against S. pneumoniae have not increased in Belgium from 999 to 28 S. pneumoniae susceptibility to moxifloxacin in Belgium Facts: cumulative percentage MIC.25 EUCAST breakpoint.5 MXF 999 MXF 28 Similar curves for 2, 23, and 24 to From data of a national collection * independent from our own collection (shown on the previous slide) No change (and even improvement) in S. pneumoniae susceptibility to moxifloxacin from 999 (pre-commercialization) to 28 (7 years after launching **) in 28, 99.3 % isolates were still below the EUCAST breakpoint (.5 mg/l) and at MIC values > -fold lower than the C max. * Non invasive respiratory tract infections ** st respiratory quinolone in BE Surveys from the Belgian Scientific Institute for Public Health for S. pneumoniae from community isolates (n=56 in 999 and 448 in 28) fgov.be Data available yearly for 999 through 28. Presented at 9th ECCMID, May 29, Helsinki, Finland (Vanhoof et al.) 8--2 Leverkusen 3
32 Conclusions (Altogether) Moxifloxacin has kept over years an excellent activity against S. pneumoniae (and wil be effective against S. aureus up to an MIC of.25- mg/l) and should, therefore stand a as a useful alternative when so-called " st line antibiotics" (for CAP, COPD or skin infections) have "stopped to work" The safety profile of moxifloxacin at 4 mg/day remains excellent with no statistically or medically significant difference with comparators (used often at a lower dose than recommended today) Thus, and based on all available evidence, the use of moxifloxacin should not be vitiated by excessive toxicity if it is prescribed for the correct indications and with due attention to the contraindications and warnings mentioned in the labeling (Van Bambeke & Tulkens, Drug Saf. 29;32(5): Tulkens et al. in preparation) Flämischer Maler Hieronymus Bosch (c45-56) zeigt großer Fantasie in seinem Triptychon Altarpiece das letzte Urteil (c5-5, Akademie, Wien) 8--2 Leverkusen 32
33 Disclosures Financial support from the Belgian Fonds de la Recherche Scientifique (and other federal and regional funding agencies) for basic research on pharmacology and toxicology of antibiotics and related topics the Public Federal Service "Public Health" for "Appropriate antibiotic use" studies in General Practice Pharmaceutical Industry for specific drug-related studies Note: all work, irrespective the source of funding, is published in peer-reviewed journals and is available from our web site * P.M. Tulkens is member of the Committee organising public campaigns for appropriate use of antibiotics in Belgium since 2 ** * ** Selected publications in relation to this presentation: "Was auch als Wahrheit oder Fabel In tausend Büchern dir erscheint, Das alles ist ein Turm zu Babel, Wenn es die Liebe nicht vereint." J.W. von Goethe Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf. 29;32(5): PubMed PMID: Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs. 27;67(6): Review. PubMed PMID: Lismond et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically-confirmed diagnosis of community-acquired pneumonia (CAP) in Belgium. Intern. J. Antimicrob. Agents, 2, in press 8--2 Leverkusen 33
Université catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium. Bayer Santé SAS, Loos, France
Communicating Comprehensive Safety Data Gained from Clinical Trials to the Scientific Community: Opportunities and Difficulties from an Example with Moxifloxacin P.M. Tulkens, 1 P. Arvis, 2 F. Kruesmann,
More informationAntibiotic selection in community-acquired pneumonia (CAP): appropriate benefit-risk profiles
Antibiotic selection in community-acquired pneumonia (CAP): appropriate benefit-risk profiles Paul M. Tulkens, MD, PhD * Françoise Van Bambeke, PharmD, PhD a Cellular and Molecular Pharmacology Unit &
More informationMoxifloxacin safety data review
Moxifloxacin safety data review Paul M. Tulkens, MD, PhD * a Cellular and Molecular Pharmacology Unit & Centre for Clinical Pharmacy Louvain Drug Research Institute Université catholique de Louvain, Brussels,
More informationFluoroquinolone selection: appropriate benefit-risk profiles
Fluoroquinolone selection: appropriate benefit-risk profiles Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD * a Cellular and Molecular Pharmacology Unit & Centre for Clinical Pharmacy Université
More informationCollateral effects of antibiotics : adverse effects and drug interactions
Meet the experts session 41 June 20th, 2009 Collateral effects of antibiotics : adverse effects and drug interactions Françoise Van Bambeke & Paul M. Tulkens Unité de Pharmacologie cellulaire et moléculaire,
More informationCommunity-acquired LRTIs in Middle East: an update from microbiology to pharmacology and toxicology
Community-acquired LRTIs in Middle East: an update from microbiology to pharmacology and toxicology Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Center for Clinical Pharmacy Louvain Drug
More informationCeftaroline: a new antibiotic for your patients?
Ceftaroline: a new antibiotic for your patients? Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Université catholique de Louvain Brussels, Belgium 11 February
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationFluoroquinolones: Parenteral use
Fluoroquinolones: Parenteral use Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Université catholique de Louvain Brussels, Belgium Middle East Anti-Infectives
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationLifting the lid off CAP guidelines
Lifting the lid off CAP guidelines Dr. Andrew M. Morris September 5, 2007 12:00-13:00 web.mac.com/idologist Objectives 1. To review the epidemiology of community-acquired pneumonia (CAP) 2. To explore
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationNot All Fluoroquinolones Are Equal
ot All Fluoroquinolones Are Equal Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Université catholique de Louvain Brussels, Belgium Singapore With approval
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 1 AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR MOXIFLOXACIN CONTAINING
More informationAntimicrobial Stewardship in Ambulatory Care
Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018
ECHO: Management of URIs Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018 Infectious causes of URIs change over time Most ARIs are viral
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationCipro and the aorta Fluoroquinolone attack? Bulat A. Ziganshin, MD, PhD and John A. Elefteriades, MD, PhD (hon)
Cipro and the aorta Fluoroquinolone attack? Bulat A. Ziganshin, MD, PhD and John A. Elefteriades, MD, PhD (hon) Aortic Institute at Yale-New Haven, Yale University School of Medicine New Haven, Connecticut,
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationLefamulin: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM
: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM Department of Critical Care, University Hospital ATTIKON National and Kapodistrian University of Athens, Medical School
More informationNovel therapies & the role of early switch and early discharge protocols for management of MRSA infections
Novel therapies & the role of early switch and early discharge protocols for management of MRSA infections Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationAntibiotic research and development in the age of superbugs
Antibiotic research and development in the age of superbugs Paul M. Tulkens, MD, PhD Emeritus Professor of Pharmacology Invited Professor (Drug Discovery & Development / Rational) therapeutic choices)
More informationA year in review in community-acquired respiratory tract infections
A year in review in community-acquired respiratory tract infections Paul M. Tulkens, MD, PhD * Cellular and Molecular Pharmacology & Center for Clinical Pharmacy Louvain Drug Research Institute, Catholic
More information3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats
Antibiotics --When Less is More Ralph Gonzales, MD, MSPH Associate Dean, Clinical Innovation School of Medicine VP, Clinical Innovation, UCSF Health Most Urgent Threats Serious Threats Multidrug-Resistant
More informationStaphylex Flucloxacillin (sodium)
Staphylex Flucloxacillin (sodium) PRODUCT INFORMATION Name of the Medicine Flucloxacillin sodium is the sodium salt of 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate. Structural
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationCommunity-Acquired Pneumonia (CAP)
Community-Acquired Pneumonia (CAP) Infectious Diseases Advisory Board 14/01/2000 - Woluwé St Lambert Colloquium Longartsen - 11/02/2000 Dr Yvan Valcke Belgian guidelines on the initial diagnostic and therapeutic
More informationCLINICAL AUDIT. Prescribing amoxicillin clavulanate appropriately
CLINICAL AUDIT Prescribing amoxicillin clavulanate appropriately Valid to September 2018 bpac nz better medicin e Background Amoxicillin clavulanate is a broad spectrum antibiotic used in primary care
More informationVI.B.2 Elements for a public summary. VI.B.2.1 Overview of disease epidemiology
VI.B.2 Elements for a public summary VI.B.2.1 Overview of disease epidemiology [Moxifloxacin] 400mg/250ml solution for infusion Moxifloxacin is a fluoroquinolone antibiotic with a broad spectrum of activity
More informationChoosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationMedDRA Important Medical Events (IME) in the EU. Patricia Mozzicato, MD MedDRA MSSO
MedDRA Important Medical Events (IME) in the EU Patricia Mozzicato, MD MedDRA MSSO Topics Covered MedDRA refresher Background of IME list Considerations in maintaining MedDRAbased term lists Inclusion/exclusion
More informationDoxycycline for strep pneumonia
Doxycycline for strep pneumonia Antibiotic Levofloxacin (Levaquin) 750 mg, 500 mg for the treatment of respiratory, skin, and urinary tract infections, user reviews and ratings. 14-12-1995 John G. Bartlett,
More informationCipro for klebsiella uti
Cipro for klebsiella uti Search Can UTI be an effective treatment for Klebsiella Pneumoniae? It is safe or dangerous to use UTI while suffering from Klebsiella Pneumoniae? 87 discussions on Treato. instock
More informationMHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative
MHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative Place picture here Nov. 14, 2017 Reminders For best sound quality, dial in at 1-800-791-2345 and enter code 11076 Please use the chat box to ask questions!
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationAmoxicillin Introduction: Mechanism of action: Pharmacology: Indications: Dosage: 12 Weeks ( 3 Months):
Amoxicillin Introduction: A semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microganisms. Mechanism of action:
More informationBacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups
Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a
More informationIs erythromycin bactericidal
Is erythromycin bactericidal Search Comparison of erythromycin, clarithromycin, azithromycin, telithromycin, roxithromycin: mechanism of action, spectrum of activity, side effects, drug interactions. Erythromycin
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationFuture design of (comparative) clinical trials or how to bring antibiotics to the bed side
Future design of (comparative) clinical trials or how to bring antibiotics to the bed side Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Université catholique
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAmoxicillin clavulanic acid spectrum
Cari untuk: Cari Cari Amoxicillin clavulanic acid spectrum 14-8-2017 Amoxicillin and clavulanate potassium (AMC), also known as augmentin, is an antibiotic used to treat bacterial infections. AMC is available
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationPrescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,
More informationGuidelines in lower respiratory tract infections: from diversity to logics
Guidelines in lower respiratory tract infections: from diversity to logics Paul Tulkens Université catholique de Louvain, Cellular and Molecular Pharmacology & Center for Clinical Pharmacy Louvain Drug
More informationGuidelines for Treatment of Urinary Tract Infections
Guidelines for Treatment of Urinary Tract Infections Overview This document details the Michigan Hospital Medicine Safety (HMS) Consortium preferred antibiotic choices for treatment of uncomplicated and
More informationCan levaquin treat group b strep
Can levaquin treat group b strep The Borg System is 100 % Can levaquin treat group b strep IBS - Symptoms, Diet and Treatment. IBS, is the common slang term or abbreviation for Irritable Bowel Syndrome
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology 400 mg film-coated tablets is a fluoroquinolone antibiotic with a broad spectrum of activity and bactericidal action. In the European
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationDrug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
More informationLyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
More informationTitle: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.0070-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationUpdate on Fluoroquinolones. Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO
Update on Fluoroquinolones Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO Potential fluoroquinolone side-effects Increased risk, greater than with most other antibiotics, for
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationTreatment of Helicobacter pylori infection in adults
APPROPRIATENESS OF CARE Treatment of Helicobacter pylori infection in adults May 2017 Helicobacter pylori (H. pylori) infection plays a major role in the development of gastroduodenal ulcer and gastric
More informationResponsible use of antibiotics
Responsible use of antibiotics Uga Dumpis MD, PhD Department of Infectious Diseases and Infection Control Pauls Stradiņs Clinical University Hospital Challenges in the hospitals Antibiotics are still effective
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationMoxifloxacin in the Treatment of Community-Acquired Pneumonia (CAP) Please see Sales Representative for Full Prescribing Information.
Moxifloxacin in the Treatment of Community-Acquired Pneumonia (CAP) Please see Sales Representative for Full Prescribing Information. AI0198 04/08 Moxifloxacin: An Advanced-Generation C8-methoxy Fluoroquinolone
More informationShort Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil
Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil D. Adam, MD PhD, Munich, Germany H. Scholz, MD PhD, Berlin,
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationObjective 1/20/2016. Expanding Antimicrobial Stewardship into the Outpatient Setting. Disclosure Statement of Financial Interest
Expanding Antimicrobial Stewardship into the Outpatient Setting Michael E. Klepser, Pharm.D., FCCP Professor Pharmacy Practice Ferris State University College of Pharmacy Disclosure Statement of Financial
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICATION PATIENT MEDICATION INFORMATION. Moxifloxacin tablets (as moxifloxacin hydrochloride)
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICATION PATIENT MEDICATION INFORMATION Pr Sandoz Moxifloxacin Moxifloxacin tablets (as moxifloxacin hydrochloride) Read this carefully before you start taking
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationWARNING: CERTAIN ANTIBIOTICS MAY CAUSE PERMANENT NERVE DAMAGE
WARNING: CERTAIN ANTIBIOTICS MAY CAUSE PERMANENT NERVE DAMAGE By Dr. Michael John Badanek, BS, DC, CNS, CTTP, DACBN, DCBCN, MSGR./CHEV In the past 36 plus years of clinical practice of Integrative/Functional
More informationCompliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings
Compliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings Jasmanda H. Wu, Ph.D., 1 David H. Howard, Ph.D., 2 John E. McGowan, Jr.,
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationClostridium difficile Surveillance Report 2016
Clostridium difficile Surveillance Report 2016 EMERGING INFECTIONS PROGRAM Clostridium difficile Surveillance Report 2016 Minnesota Department of Health Emerging Infections Program PO Box 64882, St. Paul,
More informationANTIMICROBIAL STEWARDSHIP IN SCOTLAND. Key achievements of the Scottish Antimicrobial Prescribing Group
ANTIMICROBIAL STEWARDSHIP IN SCOTLAND Key achievements of the Scottish Antimicrobial Prescribing Group Dr Jacqueline Sneddon Project Lead Scottish Antimicrobial Prescribing Group Overview of talk ScotMARAP
More informationVolume 2; Number 16 October 2008
Volume 2; Number 16 October 2008 What s new this month NHS Lincolnshire have launched a public information campaign designed to raise public awareness of the risks associated with the inappropriate use
More information